These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
534 related articles for article (PubMed ID: 34831127)
1. Inhibition of Vasculogenic Mimicry and Angiogenesis by an Anti-EGFR IgG1-Human Endostatin-P125A Fusion Protein Reduces Triple Negative Breast Cancer Metastases. Shin SU; Cho HM; Das R; Gil-Henn H; Ramakrishnan S; Al Bayati A; Carroll SF; Zhang Y; Sankar AP; Elledge C; Pimentel A; Blonska M; Rosenblatt JD Cells; 2021 Oct; 10(11):. PubMed ID: 34831127 [TBL] [Abstract][Full Text] [Related]
2. Antibody-Drug Conjugate αEGFR-E-P125A Reduces Triple-negative Breast Cancer Vasculogenic Mimicry, Motility, and Metastasis through Inhibition of EGFR, Integrin, and FAK/STAT3 Signaling. Sankar AP; Cho HM; Shin SU; Sneh T; Ramakrishnan S; Elledge C; Zhang Y; Das R; Gil-Henn H; Rosenblatt JD Cancer Res Commun; 2024 Mar; 4(3):738-756. PubMed ID: 38315147 [TBL] [Abstract][Full Text] [Related]
3. Targeted delivery of an antibody-mutant human endostatin fusion protein results in enhanced antitumor efficacy. Shin SU; Cho HM; Merchan J; Zhang J; Kovacs K; Jing Y; Ramakrishnan S; Rosenblatt JD Mol Cancer Ther; 2011 Apr; 10(4):603-14. PubMed ID: 21393427 [TBL] [Abstract][Full Text] [Related]
4. Anti-angiogenic treatment promotes triple-negative breast cancer invasion via vasculogenic mimicry. Sun H; Zhang D; Yao Z; Lin X; Liu J; Gu Q; Dong X; Liu F; Wang Y; Yao N; Cheng S; Li L; Sun S Cancer Biol Ther; 2017 Apr; 18(4):205-213. PubMed ID: 28278077 [TBL] [Abstract][Full Text] [Related]
5. Twist1 expression induced by sunitinib accelerates tumor cell vasculogenic mimicry by increasing the population of CD133+ cells in triple-negative breast cancer. Zhang D; Sun B; Zhao X; Ma Y; Ji R; Gu Q; Dong X; Li J; Liu F; Jia X; Leng X; Zhang C; Sun R; Chi J Mol Cancer; 2014 Sep; 13():207. PubMed ID: 25200065 [TBL] [Abstract][Full Text] [Related]
6. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite. Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004 [TBL] [Abstract][Full Text] [Related]
7. Ginsenoside 20(S)-protopanaxadiol inhibits triple-negative breast cancer metastasis in vivo by targeting EGFR-mediated MAPK pathway. Peng B; He R; Xu Q; Yang Y; Hu Q; Hou H; Liu X; Li J Pharmacol Res; 2019 Apr; 142():1-13. PubMed ID: 30735802 [TBL] [Abstract][Full Text] [Related]
8. AAV-P125A-endostatin and paclitaxel treatment increases endoreduplication in endothelial cells and inhibits metastasis of breast cancer. Subramanian IV; Devineni S; Ghebre R; Ghosh G; Joshi HP; Jing Y; Truskinovsky AM; Ramakrishnan S Gene Ther; 2011 Feb; 18(2):145-54. PubMed ID: 20844568 [TBL] [Abstract][Full Text] [Related]
9. Endothelium-Dependent Induction of Vasculogenic Mimicry in Human Triple-Negative Breast Cancer Cells Is Inhibited by Calcitriol and Curcumin. Morales-Guadarrama G; Méndez-Pérez EA; García-Quiroz J; Avila E; García-Becerra R; Zentella-Dehesa A; Larrea F; Díaz L Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887002 [TBL] [Abstract][Full Text] [Related]
10. Aptamer-mediated impairment of EGFR-integrin αvβ3 complex inhibits vasculogenic mimicry and growth of triple-negative breast cancers. Camorani S; Crescenzi E; Gramanzini M; Fedele M; Zannetti A; Cerchia L Sci Rep; 2017 Apr; 7():46659. PubMed ID: 28425453 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of ovarian cancer by RGD-P125A-endostatin-Fc fusion proteins. Jing Y; Lu H; Wu K; Subramanian IV; Ramakrishnan S Int J Cancer; 2011 Aug; 129(3):751-61. PubMed ID: 21225621 [TBL] [Abstract][Full Text] [Related]
12. Low Dose of Paclitaxel Combined with XAV939 Attenuates Metastasis, Angiogenesis and Growth in Breast Cancer by Suppressing Wnt Signaling. Shetti D; Zhang B; Fan C; Mo C; Lee BH; Wei K Cells; 2019 Aug; 8(8):. PubMed ID: 31416135 [TBL] [Abstract][Full Text] [Related]
13. Activation of GPER suppresses migration and angiogenesis of triple negative breast cancer via inhibition of NF-κB/IL-6 signals. Liang S; Chen Z; Jiang G; Zhou Y; Liu Q; Su Q; Wei W; Du J; Wang H Cancer Lett; 2017 Feb; 386():12-23. PubMed ID: 27836733 [TBL] [Abstract][Full Text] [Related]
14. Excellent effects and possible mechanisms of action of a new antibody-drug conjugate against EGFR-positive triple-negative breast cancer. Zhou DD; Bai WQ; Zhai XT; Sun LP; Zhen YS; Li ZR; Miao QF Mil Med Res; 2021 Dec; 8(1):63. PubMed ID: 34879870 [TBL] [Abstract][Full Text] [Related]
15. The role of WT1 isoforms in vasculogenic mimicry and metastatic potential of human triple negative breast cancer cells. Bissanum R; Lirdprapamongkol K; Svasti J; Navakanitworakul R; Kanokwiroon K Biochem Biophys Res Commun; 2017 Dec; 494(1-2):256-262. PubMed ID: 29024629 [TBL] [Abstract][Full Text] [Related]
16. KLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR gene. Roberts MS; Anstine LJ; Finke VS; Bryson BL; Webb BM; Weber-Bonk KL; Seachrist DD; Majmudar PR; Keri RA Breast Cancer Res; 2020 Jun; 22(1):66. PubMed ID: 32552913 [TBL] [Abstract][Full Text] [Related]
17. A novel humanized Frizzled-7-targeting antibody enhances antitumor effects of Bevacizumab against triple-negative breast cancer via blocking Wnt/β-catenin signaling pathway. Xie W; Zhao H; Wang F; Wang Y; He Y; Wang T; Zhang K; Yang H; Zhou Z; Shi H; Wang J; Huang G J Exp Clin Cancer Res; 2021 Jan; 40(1):30. PubMed ID: 33436039 [TBL] [Abstract][Full Text] [Related]
18. Class I histone deacetylase inhibitor suppresses vasculogenic mimicry by enhancing the expression of tumor suppressor and anti-angiogenesis genes in aggressive human TNBC cells. Maiti A; Qi Q; Peng X; Yan L; Takabe K; Hait NC Int J Oncol; 2019 Jul; 55(1):116-130. PubMed ID: 31059004 [TBL] [Abstract][Full Text] [Related]
19. Anti-EGFR Antibody-Drug Conjugate Carrying an Inhibitor Targeting CDK Restricts Triple-Negative Breast Cancer Growth. Cheung A; Chenoweth AM; Johansson A; Laddach R; Guppy N; Trendell J; Esapa B; Mavousian A; Navarro-Llinas B; Haider S; Romero-Clavijo P; Hoffmann RM; Andriollo P; Rahman KM; Jackson P; Tsoka S; Irshad S; Roxanis I; Grigoriadis A; Thurston DE; Lord CJ; Tutt ANJ; Karagiannis SN Clin Cancer Res; 2024 Aug; 30(15):3298-3315. PubMed ID: 38772416 [TBL] [Abstract][Full Text] [Related]
20. Nuclear epidermal growth factor receptor is a functional molecular target in triple-negative breast cancer. Brand TM; Iida M; Dunn EF; Luthar N; Kostopoulos KT; Corrigan KL; Wleklinski MJ; Yang D; Wisinski KB; Salgia R; Wheeler DL Mol Cancer Ther; 2014 May; 13(5):1356-68. PubMed ID: 24634415 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]